A797were incorporated into the Chinese framework with 3 main categories: resource needs (personnel, equipment), related clinical outcomes (antimicrobial resistant rate, mortality), and health economic impact (length of stay, defined daily dose). Main differences from U.S. include: 1) limited/no pharmacist involvement in routine participation in intravenous-to-oral switch programs, antibiotic dose modifications/ discontinuations; 2) inclusion of more economic outcome endpoints of AmSPs (e.g., ICU use, reduced intravenous days due to early switch, hospital onset infection rate, and restricted antimicrobial drugs use); and 3) taking a hospital business case perspective by adding a return-on-investment calculation. ConClusions: This study is the first step to develop a comprehensive AmSP evaluation framework for Chinese hospitals. It will help Chinese hospital decision-makers measure the costs and benefits associated with their specific AmSP and gain a better understanding of their value, thus creating an enhanced engagement in implementing AmSPs.

SummaryObjective: To determine whether implementation of an electronic health record (EHR) would increase the rate of prenatal Human Immunodeficiency Virus (HIV) and purified protein derivative (PPD) testing.Methods: Eligible participants received prenatal care and delivered at term at a single academic institution in March-April 2011, March-April 2012, and March-April 2013. As part of routine prenatal care, all women were tested for HIV and tuberculosis (via a PPD test) during each pregnancy. The 2011 cohort was charted on paper. The 2012 and 2013 cohorts were charted via EHR. To appear in the prenatal labs display in EHR, PPD results must be manually documented, while HIV results are uploaded automatically. Documentation of PPD and HIV tests were analyzed.Results: The 2011, 2012, and 2013 cohorts had 249, 208, and 190 patients, respectively. Complete PPD and HIV results were less likely to be charted in the 2012 EHR cohort compared to the paper chart cohort (72.1% vs. 80.1%; p=0.03). This was driven by fewer documented completed PPD tests (2011 83.9% vs. 2012 72.6%; p=0.003). PPD test documentation improved non-significantly to 86.2% in the 2013 EHR cohort (p=0.5). HIV documentation rates increased from 95.2% in the paper chart cohort to 98.6% in the 2012 EHR cohort (p=0.04), and to 98.9% in the 2013 EHR cohort (p=0.03).Conclusions: EHR implementation corresponded with a marked decrease in documentation of PPD test completion. HIV documentation rates improved. PPD results were likely charted incorrectly in provider notes due to training deficiencies and lack of standardization, which did not improve significantly after retraining.

0 1 7 ) A 3 9 9 -A 8 1 1 A411 version also takes account of other HPV-associated cancers (vaginal, vulvar, anal, penile, and selected oropharyngeal cancers) using an incidence-based approach. Parameter estimates were obtained from various sources including published literature, German cancer registry and claims data. Coverage among boys was assumed to be half the current coverage among girls. For female vaccination, the market shares of the ninevalent and bivalent vaccines were estimated to be 83% and 17%, respectively. The economic analysis was conducted from the societal perspective. Future costs and health effects were discounted at 3% per year. Results: Compared to girls-only vaccination, additional vaccination of boys prevented incremental 22,400 cervical cancer cases and 25,600 non-cervical cancer cases over a 100-year time horizon. Under base case assumptions, ICERs were € 63,200 per QALY gained when excluding the effects on non-cervical cancers and € 26,100 per QALY gained when including them. ConClusions: Considering the commonly cited threshold of € 50,000 per QALY gained, additional HPV vaccination of boys is likely to be cost-effective in Germany when including the impact on non-cervical cancers. ReseaRch PosteR PResentations -session i Disease -sPecific stuDies canceR -clinical outcomes studies Pcn1 LoweR anteRioR Resection suRgicaL comPLications in coLoRectaL canceR Patients: association with Length of stay, DischaRge to institutionaL caRe, anD 90-Day ReaDmission

Objectives: NICE of England and SMC of Scotland are responsible for issuing appraisal guidance for reimbursement of new health technologies. While both agencies consider clinical and cost-effectiveness in their decisions, they have unique policies and procedures and may yield different outcomes. We conducted an analysis of past appraisal decisions by NICE and SMC for oncology treatments to compare results and identify trends. MethOds: Oncology appraisal decisions from January 2012 to May 2017 were identified on the SMC website and Xcenda's Health Technology Assessment (HTA) Decision map. Appraisal decisions for both countries were evaluated and categorized as favorable, mixed, or unfavorable. Additionally, reported incremental cost-effectiveness ratio (ICER) and tumor type were compared for each decision. SMC decisions that were classified as withdrawn or superseded were not included. Results: A total of 91 decisions were identified for NICE, of which 64.8% (59) were favorable, 3.3% (3) were mixed, and 31.9% (29) were unfavorable. 110 decisions were identified for SMC, of which 40.9% (45) were favorable, 26.4% (29) were mixed, and 32.7% (36) were unfavorable. Between agencies, there were 53 pairs of decisions that were matched across 15 tumor types; of which, 62.3% (33) matched exactly, 24.5% (13) were similar (one agency's decision was favorable and the other agency's decision was mixed), and 13.2% (7) were in disagreement. All 18 NICE decisions with reported ICERs less than £30,000 received favorable guidance; but, the guidance for SMC was more varied. For the 25 SMC decisions with a reported ICER of less than £30,000, 12 were favorable, 10 were mixed, and 3 were unfavorable. cOnclusiOns: The majority (86.8%) of oncology HTA decisions by NICE and SMC were either the same or similar across tumor types. However, compared to NICE, there appears to be less association between the reported ICERs and SMC appraisal decision results.

No abstract